Pancreatic cancer drug Afinitor by Novartis AG's has been approved by the U.S. FDA for a rare type of pancreatic cancer that has few treatment options, reports Reuters. The Swiss drugmaker said in a statement, "Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumours (NET) of pancreatic origin."
"This marks the first approval of a treatment for this patient population in the United States in nearly 30 years," they added, Reuters reports.
TV News LIES
Establishment News Media...
There is blood on your hands!
1/2 the Story = 1 Complete Lie.
Learn How the Broadcast News
Media Deceive You!
Click Here!
Read The News That "They"
Don't Want You to Notice!
Click Here!
Explore Our Special Coverage
of the Events of 9/11/2001
Click Here!
Thursday, Nov 07th
Last update08:46:34 AM GMT
Headlines